Stocks To Buy Now

Blog


DGE’s 3rd Transparency & Aggregate Spend Summit to Discuss Ways to Improve Compliance and Efficiency of HCP Spend Reporting

DGE invites professionals and executives from pharma, biotech, and medical device companies, to attend the 3rd Transparency & Aggregate Spend Conference being held on June 3-4, 2024. The event is being organized by DGE in Philadelphia. With the growing need of transparency in compliance programs, the 3rd Transparency and Aggregate Spend Summit addresses the complex issues of the state, Open Payments, and global transparency reporting systems.

DGE (Dynamic Global Events), a life science leader in organizing B2B events, strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.

Topics of discussion:

  • CMS Keynote Address
  • Prepare for a CMS Audit
  • Improve documentation of decisions and reasoning
  • Enhance knowledge of state transparency reporting requirements
  • Navigate global compliance reporting arena
  • Ensure compliance for speaker program reporting
  • Optimize compliance monitoring
  • Uncover valuable transparency data analytics

The summit holds a discussion-based meeting format where attendees learn the latest trends for the collection, analysis, and reporting of HCP Spend data compliantly. Experts will also discuss ways of adapting to data capture, preparing audits, risk monitoring, and catering to the growing internal demand for analytics.

The event will feature the very popular interactive breakout groups dedicated to medical devices, global reporting, and collecting HCP identifying information for better acceptance submissions. (This meeting shares the same venue as AI for Life Sciences Compliance summit.)

To learn more, please visit https://ibn.fm/g6dhl.

From Our Blog

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

August 13, 2026

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual […]

Rotate your device 90° to view site.